Tyrosine kinase inhibitors (TKIs) are teratogenic. Chronic myeloid leukemia (CML) is
increasingly identified in younger patients who wish to conceive, the management of CML …

Background: Exposure to TKI has teratogenic effects in animal studies and humans. CML is
being identified in younger patients who need to continue treatment for long periods of time …

The management of CML in pregnancy is challenging with the need to balance disease
control against potential teratogenic effects of TKI therapy. In this multi-center case-cohort …

The management of patients with chronic myeloid leukemia (CML) during pregnancy
remains a matter of continuous debate. Tyrosine kinase inhibitors (TKIs) have become the …

Purpose Despite the general recommendation to avoid Tyrosine Kinase Inhibitors (TKIs) for
Chronic Myeloid Leukemia (CML) during pregnancy, unplanned pregnancies still occur …

We analyzed the management and outcomes of pregnancies of patients with chronic
myeloid leukemia at a single center over fifteen years. Among the 203 CML female patients …

Background The aim of this work was to report on the outcome of pregnancy in patients with
chronic myeloid leukaemia who were on tyrosine kinase inhibitor treatment. Patients and …

Management of pregnant patients with chronic myelogenous leukemia (CML) is challenging.
Some of the factors that need to be considered include stage of pregnancy, disease status …

Since the introduction of tyrosine kinase inhibitors (TKIs) at the beginning of the millennium,
the outlook for patients with chronic myeloid leukemia (CML) has improved remarkably. As …

Discovery of tyrosine kinase inhibitors has led to improvement in survival of chronic
myelogenous leukemia (CML) patients. Many young CML patients encounter pregnancy …